Dianthus Therapeutics (DNTH) Competitors $35.65 -0.35 (-0.97%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$35.66 +0.01 (+0.01%) As of 10/17/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENSShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Kymera Therapeutics (NASDAQ:KYMR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Which has stronger valuation & earnings, KYMR or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$44.71M95.68-$223.86M-$3.47-17.24Dianthus Therapeutics$4.85M236.40-$84.97M-$3.25-10.97 Do insiders & institutionals have more ownership in KYMR or DNTH? 47.5% of Dianthus Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, KYMR or DNTH? Kymera Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Does the media refer more to KYMR or DNTH? In the previous week, Kymera Therapeutics had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 11 mentions for Kymera Therapeutics and 9 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.75 beat Kymera Therapeutics' score of 0.16 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer KYMR or DNTH? Kymera Therapeutics presently has a consensus target price of $62.74, indicating a potential upside of 4.86%. Dianthus Therapeutics has a consensus target price of $60.88, indicating a potential upside of 70.76%. Given Dianthus Therapeutics' higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82 Is KYMR or DNTH more profitable? Kymera Therapeutics has a net margin of -616.03% compared to Dianthus Therapeutics' net margin of -2,364.56%. Kymera Therapeutics' return on equity of -31.60% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Dianthus Therapeutics -2,364.56%-34.72%-32.72% SummaryKymera Therapeutics beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.43B$6.20B$10.53BDividend YieldN/A2.28%5.70%4.82%P/E Ratio-10.9723.1685.7027.13Price / Sales236.40457.02583.17177.90Price / CashN/A46.9237.1060.81Price / Book2.9910.4112.236.52Net Income-$84.97M-$52.77M$3.33B$276.93M7 Day Performance3.45%2.31%1.17%1.93%1 Month Performance-2.99%12.59%6.85%2.19%1 Year Performance22.72%11.18%58.93%34.62% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics2.7006 of 5 stars$35.65-1.0%$60.88+70.8%+22.7%$1.15B$4.85M-10.9780News CoverageAnalyst ForecastKYMRKymera Therapeutics1.011 of 5 stars$57.55-0.6%$61.26+6.5%+28.9%$4.14B$47.07M-16.58170Analyst ForecastInsider TradePTGXProtagonist Therapeutics1.9405 of 5 stars$64.14-1.1%$68.36+6.6%+65.0%$4.03B$209.18M91.63120Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.3718 of 5 stars$41.68+2.0%$74.45+78.6%-29.6%$3.93B$1.39M-10.14210Positive NewsZLABZai Lab2.7583 of 5 stars$33.31-1.3%$56.35+69.2%+2.9%$3.77B$398.99M-16.331,869News CoverageGap UpAKROAkero Therapeutics3.5508 of 5 stars$46.04-0.1%$81.14+76.2%+72.4%$3.69BN/A-23.0230Insider TradeACADACADIA Pharmaceuticals3.9358 of 5 stars$21.59-1.0%$29.12+34.9%+36.5%$3.68B$1.02B16.23510Analyst ForecastGap UpAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600MIRMMirum Pharmaceuticals3.5889 of 5 stars$72.53-0.6%$76.50+5.5%+86.3%$3.66B$336.89M-59.94140Trending NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.5269 of 5 stars$52.70-2.1%$85.50+62.2%-52.4%$3.66B$1.53B14.02700Trending NewsAnalyst RevisionMENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031Positive News Related Companies and Tools Related Companies Kymera Therapeutics Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives Mirum Pharmaceuticals Alternatives Lantheus Alternatives Jyong Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts